<div class="headers"><div>Figure 3. Changes in systolic BP for the overall populations and Latin American subgroups of the (A) PBO-controlled studies at Week 26 and (B) active-controlled studies at Week 52.BP, blood pressure; PBO, placebo; MET, metformin; SU, sulfonylurea; LS, least squares; SE, standard error; CI, confidence interval; CANA, canagliflozin; SITA, sitagliptin; GLIM, glimepiride; NS not significant. *P50.001 versus PBO/SITA. yStatistical comparisons were not performed in the post hoc analysis of patients from Latin America. zP ¼ NS versus PBO. xStatistical comparisons were not performed (not prespecified).</div></div><table class='gmisc_table' style='border-collapse: collapse; margin-top: 1em; margin-bottom: 1em;' >
<tbody>
<tr style='border-top: 2px solid grey;'>
<td style='border-top: 2px solid grey; text-align: left;'><p style="" class="">Figure 3. Changes in systolic BP for the overall populations and Latin American subgroups of the (A) PBO-controlled studies at Week 26 and (B) active-controlled studies at Week 52.</p></td>
</tr>
<tr>
<td style='border-bottom: 2px solid grey; text-align: left;'><p style="" class="">BP, blood pressure; PBO, placebo; MET, metformin; SU, sulfonylurea; LS, least squares; SE, standard error; CI, confidence interval; CANA, canagliflozin; SITA, sitagliptin; GLIM, glimepiride; NS not significant. *P50.001 versus PBO/SITA. yStatistical comparisons were not performed in the post hoc analysis of patients from Latin America. zP ¼ NS versus PBO. xStatistical comparisons were not performed (not prespecified).</p></td>
</tr>
</tbody>
</table>
